Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
RR 0.74 [0.62, 0.89]
7 studies
GRADE not reported
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF may leads to lower oral mucositis (severe) compared with placebo (low certainty).
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF may leads to lower oral mucositis (any severity) compared with placebo (low certainty).
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to higher improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to higher mucositis eradicated compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to lower time to heal mucositis (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Allopurinol mouthrinse led to lower oral mucositis (moderate to severe) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.66 [0.5, 0.86]
2 studies
GRADE not reported
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Allopurinol mouthrinse showed no clear difference in oral mucositis (any severity) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.77 [0.5, 1.19]
4 studies
GRADE not reported
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional salvianolic acid B (very low certainty).
1 finding from 1 review
Salivary S. mutans level · Patients with aggressive periodontitis
Salivary Actinobacillus and S. mutans levels were negatively associated.
1 finding from 1 review
OR 0.08 [0.01, 0.85]
1 study
GRADE not reported
Physician Global Assessment (clinical signs, complete response) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in physician Global Assessment (clinical signs, complete response) compared with placebo; GRADE not reported.
1 finding from 1 review
Partial response (>33% improvement) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in partial response (>33% improvement) compared with placebo; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported.
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower pain (mean score) compared with topical curcumin (low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean score) compared with intralesional BCG-polysaccharide nucleic acid (BCG-PSN); GRADE not reported.
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to higher clinical score compared with photodynamic therapy (low certainty).
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes clinical resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse effects compared with topical ciclosporin; GRADE not reported.
1 finding from 1 review